Oncolytic Virotherapy
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| H101 Combined With Camrelizumab for Recurrent Cervical Cancer (NCT05234905) | Zhejiang Cancer Hospital | 2022-03-01 |
Track Oncolytic Virotherapy automatically
Every clearance here is in the API, with alerts when new ones post.